stockrowEli Lilly and Company
LLY Healthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.
- Revenue
- +38.6%
- EPS
- +16.3%
- Free cash flow
- +21.8%
- Total debt
- +15.0%
Quarter to September 2026, against a year earlier
Follow LLY
Alert me
Eli Lilly and Company (LLY) Net income
Eli Lilly and Company's net income for fiscal 2025 was $20.6B, up 94.9% from $10.6B in fiscal 2024. Over the twelve months to 30 September 2026 it was $27.6B. Over the past ten years it has ranged from −$204.1M (fiscal 2017) to $20.6B (fiscal 2025) — the current reading is the highest in ten years. Eli Lilly and Company ranks 1st of 21 Drug Manufacturers General companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $20.6B | 94.90% |
| FY2024 | $10.6B | 102.10% |
| FY2023 | $5.2B | (16.09%) |
| FY2022 | $6.2B | 11.88% |
| FY2021 | $5.6B | (9.88%) |
| FY2020 | $6.2B | (25.54%) |
| FY2019 | $8.3B | 157.38% |
| FY2018 | $3.2B | — |
| FY2017 | −$204.1M | — |
| FY2016 | $2.7B | 13.67% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $6.5B | (9.08%) |
| Jun 2026 | $7.1B | (4.07%) |
| Mar 2026 | $7.4B | 11.42% |
| Dec 2025 | $6.6B | 18.92% |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| LLY Eli Lilly and Company | $27.6B |
| JNJ Johnson & Johnson compare | $16.1B |
| AZN AstraZeneca PLC compare | $13.3B |
| ABBV AbbVie Inc. compare | $10.3B |
| NVS Novartis AG compare | $10.0B |
| AMGN Amgen Inc. compare | $9.4B |
| PFE Pfizer Inc. compare | $4.1B |
| MRK Merck & Co., Inc. compare | $3.2B |
| GILD Gilead Sciences, Inc. compare | −$3.9B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on LLY
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement